



EUROPEAN
COMMISSION

European
Research Area

FP7 Cooperation Work Programme: Health-2010 Topics and contact points

Date of publication: 30 July 2009.

Call identifiers:	Indicative budgets	Deadlines
FP7-HEALTH-2010-two-stage	EUR 205 million	29 October 2009 (for stage 1 proposals)
FP7-INFLUENZA-2010	EUR 12 million	29 October 2009
FP7-HEALTH-2010-single-stage	EUR 333.5 million	19 November 2009
FP7-ERANET-2010-RTD	EUR 6 million	19 January 2010
FP7-AFRICA-2010	EUR 39 million	14 January 2010
FP7-HEALTH-2010-Alternative Testing	EUR 25 million	3 February 2010
TOTAL	EUR 620.5 million	

Funding schemes:

CP-FP (Collaborative Project-Small or medium-scale Focused research project);
CP-IP (Collaborative Project-Large scale Integrating Project); NoE (Network of Excellence)
CA (Coordination and Support Action - Coordinating Action)
SA (Coordination and Support Action - Supporting Action)

1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH

1.1 HIGH-THROUGHPUT RESEARCH

- **1.1-1: Harmonisation of phenotyping and biosampling for human large-scale clinical research biobanks.**

FP7-HEALTH-2010-SINGLE-STAGE

CP-IP(s), min € 6m – max € 12m (max 1 project)

- **1.1-2: Genomics and genetic epidemiology of multifactorial diseases - FP7-ERANET-2010-RTD**

CA, max € 2m (max 1 project)

Scientific officer: **Iiro EEROLA** (iiro.eerola@ec.europa.eu) – (UNIT F.4)

- **1.1-3: High-throughput analysis of post-translational modifications of proteins - FP7-HEALTH-2010-SINGLE-STAGE**

SICA (target region: China) CP-FP, max € 3m (max 1 project)

Scientific officer: **Thomasz DYLAG** (thomasz.dylag@ec.europa.eu) – (UNIT F.4)

1.2 DETECTION, DIAGNOSIS AND MONITORING

- **1.2-1: Tools for the identification and the detection of biomarkers in clinical samples and patients**

FP7-HEALTH-2010-TWO-STAGE

CP-FP, max € 6m (1 or more projects)

Scientific officers: **Jean-Luc SANNE** (jean-luc.sanne@ec.europa.eu);
Torbjörn INGEMANSSON (torbjorn.ingemansson@ec.europa.eu);
Philippe JEHENSON (philippe.jehenson@ec.europa.eu);- (UNIT F.5)

- **1.2-2: Stratification approaches and methodologies to select from a wide range of biomarkers relevant candidates for clinical validation - FP7-HEALTH-2010-SINGLE-STAGE**

SA, max € 0.5m (max 1 project)

- **1.2-3: Harmonization, validation and standardisation in genetic testing - FP7-HEALTH-2010-SINGLE-STAGE**

CA, max € 2m (max 1 project)

Scientific officer: **Jean-Luc SANNE** (jean-luc.sanne@ec.europa.eu) - (UNIT F.5)

- **1.2-4: Early events in acute hepatitis C virus (HCV) infection with the aim to identify new biomarkers - FP7-HEALTH-2010-SINGLE-STAGE**
SICA for Mediterranean Partner Countries, CP-FP, max € 3m (1 or more projects)

Scientific officers: **Arnd HOEVELER** (arnd.hoeveler@ec.europa.eu); **David GANCBERG** (david.gancberg@ec.europa.eu) (UNIT F.5)

1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES

Closed in WP 2010

1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS

- **1.4-1: Translational research on cell-based immunotherapy - FP7-HEALTH-2010-SINGLE-STAGE**
CP-IP(s), min € 6m - max € 12m (1 or more projects)

Scientific officers: **Jürgen SAUTTER** (juergen.sautter@ec.europa.eu); **Charles KESSLER** (charles.kessler@ec.europa.eu); **David GANCBERG** (david.gancberg@ec.europa.eu) - (UNIT F.5)

2. TRANSLATING RESEARCH FOR HUMAN HEALTH

2.1 INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY

- **2.1-1: Large-scale data gathering - FP7-HEALTH-2010-SINGLE-STAGE**

2.1.1-1: Large-scale efforts in mouse functional genomics to determine the functions of genes and their involvement in disease - CP-IP(s), min € 6m - max € 12m (max 1 project)

Scientific officer: **Christian DESAINTE** (christian.desaintes@ec.europa.eu) - (UNIT F.4)

2.1.1-2: Coordination action(s) on standards in large-scale data gathering - CA, max € 2m (1 or more projects)

Scientific officer: **Tomasz DYLAG** (tomasz.dylag@ec.europa.eu) - (UNIT F.4)

- **2.1-2: Systems biology**

FP7-HEALTH-2010-TWO-STAGE

2.1.2-1: Tackling human diseases through systems biology approaches - CP-IP(s), min € 6m - max € 12m (1 or more projects)

Scientific officers: **Frederick MARCUS** (frederick.marcus@ec.europa.eu); **Christina KYRIAKOPOULOU** (christina.kyriakopoulou@ec.europa.eu) - (UNIT F.4)

2.1.2-2: Establishing the foundations to enable systems biology of complex biological processes relevant to human health - NoE, max € 12m (1 or more projects)

Scientific officers: **Jacques REMACLE** (Jacques.remacle@ec.europa.eu); **Christina KYRIAKOPOULOU** (christina.kyriakopoulou@ec.europa.eu) - (UNIT F.4)

FP7-HEALTH-2010-SINGLE-STAGE

2.1.2-3: Developing new and improving existing mathematical algorithms for systems biology

SICA, CP-FP, with focus on EECA, max € 3m (max 1 project)

Scientific officer: **Christina KYRIAKOPOULOU** (christina.kyriakopoulou@ec.europa.eu) - (UNIT F.4)

2.2 RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING

- **2.2-1: Brain and brain-related diseases**

No topics at this time (under consideration for possible initiatives linked to Joint Programming for research on neurodegenerative diseases)

- **2.2-2: Human Development and ageing**

FP7-HEALTH-2010-TWO-STAGE

2.2.2-1: Role of early-life developmental processes in longevity determination

CP-IP, min € 6m - max € 12m (max. 1 project)

2.2.2-2: Homeostasis in human development and its effects on lifespan - CP-FP, max € 6m (max 1 project)

2.2.2-3: Integrative systems biology and comparative genomics for studying human ageing

CP-IP, min € 6m – max € 12m (max 1 project)

2.2.2-4: Markers of cellular senescence for human ageing – CP-FP, max € 3m (max 1 project)

FP7-HEALTH-2010-SINGLE-STAGE

2.2.2-5: Frailty and its implications in modern society - SA, max € 0,5m (max 1 project)

Scientific officer: **Beatrice LUCARONI** (Beatrice.lucaroni@ec.europa.eu) – (UNIT F.4)

2.3 TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH

- **2.3-1: Anti-microbial drug resistance including fungal pathogens - Closed in WP 2010**
- **2.3-2: HIV/AIDS, malaria and tuberculosis**

FP7-HEALTH-2010-SINGLE-STAGE

2.3.2-1: Target characterisation and hit-to-lead progression in tuberculosis (TB) drug development.

CP-IP, min € 6m – max € 12m (max 1 project)

Scientific officer: Hannu LAANG (hannu.laang@ec.europa.eu) - (UNIT F.3)

2.3.2-2: Lead optimisation and late preclinical development in tuberculosis (TB) drugs.

CP-FP, max € 6m (1 or more projects)

Scientific officer: Hannu LAANG (hannu.laang@ec.europa.eu) - (UNIT F.3)

2.3.2-3: European network of cohort studies on HIV/AIDS - NoE, max € 12m (max 1 project)

Scientific officer: Alessandra MARTINI (alessandra.martini@ec.europa.eu) - (UNIT F.3)

FP7-HEALTH-2010-AFRICA

2.3.2-4: Controlling Malaria by hitting the vector: new or improved – vector control tools.

SICA (target region: Africa) CP-IP min € 6m – max € 12m (max 1 project) -

Scientific officer: Andreas HOLTEL (andreas.holtel@ec.europa.eu); - (UNIT F.3)

- **2.3-3: Potentially new and re-emerging epidemics**

FP7-HEALTH-2010-SINGLE-STAGE

2.3.3-1: Biology and control of vector-borne infections in Europe - CP-IP, min € 6m - max € 12m (max 1 project)

2.3.3-2: Drug lead discovery against RNA viruses - CP-IP, min € 6m - max € 12m (max 1 project)

2.3.3-3: Integrated disease-specific research on West Nile Virus infections, Chikungunya and/or Crimean Congo Haemorrhagic Fever - CP-FP, max € 3m (1 or more projects)

FP7-INFLUENZA-2010

2.3.3-4: Novel therapeutics against influenza - CP-FP, max € 6m (1 or more projects)

Scientific officer: Cornelius SCHMALTZ (Cornelius.schmaltz@ec.europa.eu) - (UNIT F.3)

- **2.3-4: Neglected infectious diseases - FP7-HEALTH-2010-SINGLE-STAGE**

2.3.4-1: Vaccines for childhood bacterial diarrhoeal diseases.

SICA (target region: all ICPC) CP-IP, min € 6m - max € 12m (max 1 project)

2.3.4-2: Comprehensive control of Neglected Infectious Diseases.

SICA (target region: all ICPC) CP-FP, max € 6m (1 or more projects)

2.3.4-3: Next generation of researchers for Neglected Infectious Diseases.

CA, max € 2m (1 or more projects)

Scientific officer: Ole OLESEN (ole.olesen@ec.europa.eu) - (UNIT F.3)

2.4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES

- **2.4-1: Cancer**

FP7-ERANET-2010-RTD

2.4.1-1: ERA-NET on translational cancer in Europe - CA, max € 2m (max 1 project)

Scientific officer: Elmar NIMMESGERN (elmar.nimmesgern@ec.europa.eu) – (UNIT F.2)

FP7-HEALTH-2010-SINGLE-STAGE

2.4.1-2: Structuring translational cancer research between cancer research centers in Europe.

NoE, max € 12m (max 1 project)

Scientific officer: Jan VAN DE LOO (jan-willem.van-de-loo@ec.europa.eu) – (UNIT F.2)

2.4.1-3: Structuring clinical research in paediatric and adolescent oncology in Europe

NoE, max € 12m (max 1 project)

Scientific officer: Jan VAN DE LOO (jan-willem.van-de-loo@ec.europa.eu) – (UNIT F.2)

FP7-AFRICA-2010

2.4.1-4: Infectious agents and cancer in Africa - SICA (target region: Africa), CP-FP, max € 3m (1 or more projects)

Scientific officer: Dominika TRZASKA (dominika.trzaska@ec.europa.eu) – (UNIT F.2)

FP7-HEALTH-2010-TWO-STAGE

2.4.1-5: Structuring clinical trials on rare cancers in adults - CP-FP, max € 6m (1 or more projects)

Scientific officer: **Elmar NIMMESGERN** (Elmar.nimmesgern@ec.europa.eu) - **(UNIT F.2)**

2.4.1-6: Translational research on cancers with poor-prognosis - CP-FP, max € 3m (1 or more projects)

Scientific officer: **Dominika TRZASKA** (dominika.trzaska@ec.europa.eu) – **(UNIT F.2)**

2.4.1-7: Predicting long-term side effects to cancer therapy - CP-FP, max € 6m (1 or more projects)

Scientific officer: **Dominika TRZASKA** (dominika.trzaska@ec.europa.eu) – **(UNIT F.2)**

2.4.1-8: Predicting individual response and resistance to cancer therapy - CP-FP, max €6m (1 or more projects)

Scientific officer: **Jan VAN DE LOO** (jan-willem.van-de-loo@ec.europa.eu) – **(UNIT F.2)**

2.4.1-9: Optimising the delivery of (chemo)radiotherapy and/or surgery to cancer patients

CP-FP, max € 6m (1 or more projects)

Scientific officer: **Elmar NIMMESGERN** (Elmar.nimmesgern@ec.europa.eu) - **(UNIT F.2)**

- **2.4-2: Cardiovascular diseases** - **FP7-HEALTH-2010-SINGLE-STAGE**

2.4.2-1: Reducing in-stent thrombosis - CP-FP, max € 6m (max 1 project)

2.4.2-2: New approaches to reduce ischemic damage to the heart - CP-FP, max € 2m (max 1 project)

2.4.2-3: Identifying new therapeutic targets in atrial fibrillation - CP-IP, min € 6m – max € 12m (max 1 project)

2.4.2-4: Diastolic heart failure - CP-IP, min € 6m – max €12m (max 1 project)

Scientific officer: **Virginija DAMBRAUSKAITE** (virginija.dambrauskaite@ec.europa.eu); **(UNIT F.2)**

- **2.4-3: Diabetes and obesity** - **Closed in WP 2010**

- **2.4-4: Rare diseases**

FP7-HEALTH-2010-SINGLE-STAGE

2.4.4-1: Clinical development of substances with a clear potential as orphan drugs.

CP-FP, max € 6m (1 or more projects)

FP7-ERANET-2010-RTD

2.4.4-2: ERA-NET on rare diseases.CP-FP, max € 6m (1 or more projects) - CA, max € 2m (max 1 project)

Scientific officer: **Catherine BERENS** (catherine.berens@ec.europa.eu) - **(UNIT F.2)**

- **2.4-5: Other chronic diseases** - **FP7-HEALTH-2010-SINGLE-STAGE**

2.4.5-1: Investigation of the mechanisms of initiation of allergic response, genetic predisposition, biomarkers and identification of targets for therapy - CP-IP, min € 6m - max € 12m (max 1 project)

2.4.5-2: Infection and dysbiosis as the triggers of the development of inflammatory processes in allergies and autoimmune diseases - CP-FP, max € 6m (1 or more projects)

Scientific officer: **Grigorij KOGAN** (grigorij.kogan@ec.europa.eu) **(UNIT F.2)**

3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS

3.1 TRANSLATING CLINICAL RESEARCH INTO PRACTICE

- **3.1-1: Better understanding of dissemination and implementation strategies** - **FP7-HEALTH-2010-TWO-STAGE**
CP-FP, max € 3m (1 or more projects)

Scientific officer: **Jan PAEHLER** (jan.paehler@ec.europa.eu) - **(UNIT F.2.01)**

3.2 QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS

- **3.2-1: Financing systems' effect on quality of healthcare** - **FP7-HEALTH-2010-SINGLE-STAGE**
CP-FP, max € 3m (1 or more projects)

- **3.2-2: Risk adjustment algorithms for better health insurance coverage** - **FP7-HEALTH-2010-SINGLE-STAGE**
CP-FP, max € 3m (1 or more projects)

Scientific officer: **Oyvind HOPE** (oyvind.hope@ec.europa.eu) - **(UNIT F.2.01)**

3.4 INTERNATIONAL PUBLIC HEALTH & HEALTH SYSTEMS (Coordinated call for AFRICA)

FP7-AFRICA-2010

- **3.4-1: Develop and assess key interventions and policies to address the human resource crisis in the health sector**
SICA (ACP) CP-FP, max € 3m (1 or more projects)
- **3.4-2: Feasibility and community effectiveness of innovative intervention packages for maternal & new-born health in Africa**
SICA (ACP/MPC) CP-FP, max € 3m (1 or more projects)
- **3.4-3: Building sustainable capacity for research for health in Africa - CA (ACP/MPC) max € 2m (max 1 project)**
- **3.4-4: Assessment of migrants' health, disease patterns and impact on health systems.**
CA (MPC) max € 2m (max 1 project)

FP7-HEALTH-2010-SINGLE-STAGE

- **3.4-5: Assessment of migrants' health, disease patterns and impact on health systems.**
CA (LA, MPC) max € 2m (max 1 project)
- **3.4-6: Impact and cost-effectiveness of existing major health programmes.**
SICA (ICPC) CP-FP, max € 3m (1 or more projects)
- **3.4-7: Financing models for accessible health care - SICA (ICPC) CP-FP, max € 3m (1 or more projects)**

Scientific officer: **Albrecht JAHN** (albrecht.jahn@ec.europa.eu) - (UNIT F.2.01)

4. OTHER ACTIONS ACROSS THE HEALTH THEME

4.1 COORDINATION & SUPPORT ACTIONS ACROSS THE THEME

- **4.1-1: Promoting participation of high-technology research-intensive SMEs, operating in the Health sector**
CA, max € 2m (max 1 project) - **FP7-HEALTH-2010-SINGLE-STAGE**

Scientific officer: **Ludovica SERAFINI** (ludovica.serafini@ec.europa.eu) - (UNIT F.1)

4.2 RESPONDING TO EU POLICY NEEDS

FP7-HEALTH-2010-SINGLE-STAGE

- **4.2-1: Off-Patent Medicines for Children - CP-FP, max € 6m (1 or more projects)**
- **4.2-2: International Paediatric Initiative - NoE, max € 12m (max 1 project)**
- **4.2-3: Adverse Drug Reaction Research - CP-FP, max € 3m (1 or more projects)**

Scientific officer: **Fergal DONNELLY – (UNIT F.5)** (fergal.donnely@ec.europa.eu);

- **4.2-4: International Pluripotent Stem Cell Registry - CA, max € 2m (max 1 project)**

Scientific officer: **Jacques REMACLE** (Jacques.remacle@ec.europa.eu); (UNIT F.4)

- **4.2-5: Methodology to evaluate and monitor health policy implementation and performance of EU-funded interventions in developing countries - SICA (all ICPC), CP-FP, max € 3m (max 1 project)**

Scientific officer: **Albrecht JAHN** (albrecht.jahn@ec.europa.eu) - (UNIT F.2)

- **4.2-6: Impact of EU legislation on health research - SA, max € 0.5m (1 or more projects)**

Scientific officer: **Joana NAMORADO** (joana.namorado@ec.europa.eu) - (UNIT F.1)

- **4.2-7: International forum for European life sciences funders and performers - CA, max € 2m (max 1 project)**

Scientific officer: **Jacques REMACLE** (Jacques.remacle@ec.europa.eu) - (UNIT F.4)

- **4.2-8: Coordination action in support of the implementation by participating states of a Joint Programming Initiative for combating neurodegenerative diseases, in particular Alzheimer's disease**
CA, max € 2m (max 1 project)

Scientific officer: **Patrizia TOSETTI** (Patrizia.tosetti@ec.europa.eu) - (UNIT F.2)

FP7-HEALTH-2010-ALTERNATIVE-TESTING

- **4.2-9: Towards the replacement of repeated dose systemic toxicity testing in human safety assessment**

4.2.9-1: Optimisation of current methodologies and development of novel methods to achieve functional differentiation of human-based target cells *in vitro* - CP-IP, min € 4m - max € 5m (max 1 project)

4.2.9-2: Exploitation of organ-simulating cellular devices as alternatives for long-term toxicity testing
CP-IP, min € 4m - max € 5m (max 1 project)

4.2.9-3: Establishment of endpoints and intermediate markers in human-based target cells with relevance for repeated dose systemic toxicity testing - CP-IP, min € 3.5m - max € 4.5m (max 1 project)

4.2.9-4: Computational modelling and estimation techniques - CP-IP, min € 2.5m - max € 3.5m (max 1 project)

4.2.9-5: Systems biology for the development of predictive causal computer models
CP-IP, min € 4m - max € 5m (max 1 project)

4.2.9-6: Integrated data analysis and servicing - CP-IP, min € 2m - max € 3m (max 1 project)

4.2.9-7: Coordination project - CA, max € 1.5m (max 1 project)

Scientific officer: **Jürgen BÜSING** (Juergen.buesing@ec.europa.eu) - **(UNIT F.5)**

LEGAL NOTICE

Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use which might be made of the following information.